Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6A Suppl
|
| pubmed:dateCreated |
1997-1-17
|
| pubmed:abstractText |
The combined use of total prostate-specific antigen (PSA), clinical stage, and Gleason score accurately predicts final pathologic stage for men with clinically localized prostate cancer. Recently, the free/ total PSA ratio has been proposed as an adjunct for early detection of prostate cancer. We examined the association between free/total PSA and pathologic stage.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0090-4295
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
48
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
51-4
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8973700-Aged,
pubmed-meshheading:8973700-Humans,
pubmed-meshheading:8973700-Male,
pubmed-meshheading:8973700-Middle Aged,
pubmed-meshheading:8973700-Neoplasm Staging,
pubmed-meshheading:8973700-Predictive Value of Tests,
pubmed-meshheading:8973700-Prospective Studies,
pubmed-meshheading:8973700-Prostate-Specific Antigen,
pubmed-meshheading:8973700-Prostatic Neoplasms
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
|
| pubmed:affiliation |
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institution, Baltimore, Maryland 21287-2101, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|